Detalhe da pesquisa
1.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med
; 389(24): 2256-2266, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870955
2.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38043558
3.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621400
4.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med
; 385(13): 1196-1206, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551229
5.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990608
6.
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.
Br J Cancer
; 129(3): 475-485, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37365284
7.
Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
Curr Oncol Rep
; 25(6): 609-621, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36988735
8.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(11): 1389-1397, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261050
9.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581798
10.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
; 381(2): 121-131, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31157964
11.
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
BMC Med
; 20(1): 112, 2022 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35331214
12.
BRAF inhibition and the spectrum of granulomatous reactions.
J Am Acad Dermatol
; 87(3): 605-613, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34715287
13.
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer.
Cancer
; 127(14): 2587-2594, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798267
14.
To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma.
Cancer
; 127(13): 2333-2341, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33844296
15.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
BJU Int
; 128(5): 642-651, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34028967
16.
UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).
BJU Int
; 128(3): 331-342, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33682320
17.
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Cancer
; 125(8): 1341-1349, 2019 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30768786
18.
A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
Br J Cancer
; 120(12): 1113-1119, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31105270
19.
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Oncologist
; 24(9): 1188-1194, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30952818
20.
Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer Patients Using Nanoparticle-Mediated Ranking.
Anal Chem
; 91(15): 9348-9355, 2019 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31264404